ENGN
enGene Holdings Inc

935
Loading...
Loading...
News
all
press releases
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
enGene Holdings Inc. (Nasdaq: ENGN or enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as...
Business Wire·7mo ago
News Placeholder
More News
News Placeholder
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as...
Business Wire·7mo ago
News Placeholder
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
enGene Holdings Inc. (Nasdaq: ENGN, or enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as...
Business Wire·8mo ago
News Placeholder
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as...
Business Wire·9mo ago
News Placeholder
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
enGene Holdings Inc. (Nasdaq: ENGN, or enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as...
Business Wire·9mo ago
News Placeholder
enGene to Participate in Upcoming Investor Conferences
enGene Holdings Inc. (Nasdaq: ENGN or enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as...
Business Wire·10mo ago
News Placeholder
enGene to Participate in Guggenheims Inaugural Healthcare Innovation Conference
enGene Holdings Inc. (Nasdaq: ENGN or enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as...
Business Wire·10mo ago
News Placeholder
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as...
Business Wire·11mo ago
News Placeholder
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
enGene Holdings Inc. (Nasdaq: ENGN or enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as...
Business Wire·11mo ago
News Placeholder
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as...
Business Wire·1y ago

Latest ENGN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.